Befam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.55 M
- Company Age 48 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.90 M
- Revenue Growth 2.09%
- Profit Growth -8.18%
- Ebitda -14.36%
- Net Worth 10.87%
- Total Assets 14.20%
About Befam Pharmaceuticals
Befam Pharmaceuticals Pvt Ltd (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 December 1976 and has a history of 48 years and two months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.55 M.
The company currently has active open charges totaling ₹2.90 M.
Pinaki Bhattacharjee, Gautam Bhattacharjee, and Manjulika Bhattacharjee serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24234WB1976PTC030819
- Company No.
030819
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Dec 1976
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Befam Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pinaki Bhattacharjee  | Director | 01-Jul-2009 | Current |
| Gautam Bhattacharjee | Director | 28-Aug-1979 | Current |
| Manjulika Bhattacharjee | Director | 11-Jul-1980 | Current |
Financial Performance of Befam Pharmaceuticals.
Befam Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced modest growth in revenue, with a 2.09% increase. The company also saw a slight decrease in profitability, with a 8.18% decrease in profit. The company's net worth Soared by an impressive increase of 10.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Befam Pharmaceuticals?
In 2017, Befam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.90 M
₹0
Charges Breakdown by Lending Institutions
- Allahabad Bank : 0.29 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Apr 2007 | Allahabad Bank | ₹2.90 M | Open |
How Many Employees Work at Befam Pharmaceuticals?
Befam Pharmaceuticals has a workforce of 37 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Befam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Befam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
